How would you manage a HR+/HER2+ breast cancer patient with no response during neoadjuvant TCHP?
Answer from: Medical Oncologist at Academic Institution
A few thoughts:
Although we know that patients with ER+/HER2+ are less likely to respond to neoadjuvant chemo and dual HER2-targeted therapy than those who are ER-/HER2+, I would confirm that the patient is truly HER2+; if the diagnosis was made by IHC, would send FISH or CISH.
If t...
Comments
Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital Thank you for your response.
Off study - would yo...
Medical Oncologist at Warren Alpert Medical School of Brown University We don't know the benefit of subsequent neratinib ...
Thank you for your response. Off study - would yo...
We don't know the benefit of subsequent neratinib ...